Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in Controls
Launched by H. LUNDBECK A/S · May 25, 2012
Trial Information
Current as of June 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- All subjects must have:
- • a Hamilton Depression Rating Scale (HAM-D17) total score ≤ 7
- Subjects remitted from depression must:
- • be in remission from recurrent depression having suffered from at least two previous Major Depressive Episodes (MDEs)
- • have received prescribed treatment with an antidepressant or a recognised psychotherapy for depression for a previous MDE
- • report present subjective cognitive dysfunction
- • not have been treated with antidepressants or received other psychotherapy for depression for at least six weeks prior to screening visit
- Control group subjects must:
- • have no history of MDEs
- • have no history of MDEs in a biological parent or other first degree relative as reported by the subject
- • not report present subjective cognitive dysfunction
- • never have been treated with antidepressants or psychotherapy
- Exclusion Criteria:
- • The subject is, in the opinion of the investigator, unlikely to comply with the clinical study protocol or is unsuitable for any other reason
- • Other inclusion and exclusion criteria may apply.
About H. Lundbeck A/S
H. Lundbeck A/S is a global pharmaceutical company dedicated to improving the quality of life for patients with brain disorders. Founded in 1915 and headquartered in Denmark, Lundbeck specializes in research, development, manufacturing, and marketing of innovative treatments for conditions such as depression, schizophrenia, and Alzheimer's disease. With a strong commitment to neuroscience, Lundbeck invests significantly in clinical trials to advance the understanding and treatment of psychiatric and neurological disorders, aiming to deliver effective solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Headington, , United Kingdom
Patients applied
Trial Officials
Email contact via H. Lundbeck A/S
Study Director
LundbeckClinicalTrials@lundbeck.com
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials